# E-DRUG: osteoporosis and drugs **URL:** \ **Category:** e-drug\ **Created:** [March 28, 1997, 5:36pm UTC](https://talk.edrugplus.org/t/e-drug-osteoporosis-and-drugs/540 "1997-03-28T17:36:49Z")\ **Posts on this page:** 1\ **Page:** 1
**Author:** ![David\_Henry1](https://avatars.discourse-cdn.com/v4/letter/d/a8b319/32.png) [@David\_Henry1](https://talk.edrugplus.org/u/David_Henry1)\ **Post date:** [March 28, 1997, 5:36pm UTC](https://talk.edrugplus.org/t/e-drug-osteoporosis-and-drugs/540/1 "1997-03-28T17:36:49Z")
Regarding the information on benefits and risks of various drugs for osteoporosis requested by Arturo Marti-Carvajal, the musculoskeletal group in the Cochrane Collaboration is pulling this together in a series of sytematic reviews. The Vit D review is on the most recent version of the Cochrane Library and details of progress about the other reviews (some of which are fairly close to publication) can be obtained from the Musculoskeletal Group convenor - Beverley Shea who works at Ottawa Civic Hospital. her e-mail address is bshea@CIVICH.OTTAWA.ON.CA In Newcastle we have completed a review of the evidence for the efficacy of estrogens in osteoporosis and fracture. This is a little out of date but was written for the Australian government and can be obtained from me by writing (rather than e-mail) to the mailing address given below. This report does not include information on the risks. David Henry David Henry, Discipline of Clinical Pharmacology, Faculty of Medicine and Health Sciences, The University of Newcastle, Newcastle Mater Hospital, Waratah, NSW, AUSTRALIA Phone +61 (0)49 211856 Fax +61 (0)49 602088 Home +61 (0)49 505576 mddah@alinga.newcastle.edu.au -- Send mail for the `E-Drug' conference to `e-drug@usa.healthnet.org'. Mail administrative requests to `majordomo@usa.healthnet.org'. For additional assistance, send mail to: `owner-e-drug@usa.healthnet.org'.